Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. - Abstract - Europe PMC
PDF) Ruxolitinib for the Treatment of Essential Thrombocythemia
PDF) Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study | Claire Harrison - Academia.edu
Risk stratification of patients with essential thrombocythemia: therapeutic implications
How we diagnose and treat essential thrombocythaemia - Alimam - 2015 - British Journal of Haematology - Wiley Online Library
Management of Essential Thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 Trial
HYDROXYCARBAMIDE – MYELOPROLIFERATIVE NEOPLASMS
Nordic care program for patients with Essential Thrombocythemia, Polycythemia Vera and Primary Myelofibrosis
Advancing Our Clinical Perspectives in Haematology – What is Your Approach? - touchONCOLOGY
Essential thrombocythaemia and its neurological complications | Practical Neurology
Bone marrow trephine biopsy findings in essential thrombocythemia - Flora - 2011 - American Journal of Hematology - Wiley Online Library
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study - The Lancet
LCA HAEMATOLOGY GUIDELINES: MYELOPROLIFERATIVE NEOPLASMS
Essential Thrombocythemia
Essential thrombocythemia - Wikipedia
Essential thrombocythemia treatment algorithm 2018 | Blood Cancer Journal
Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation | Haematologica
Network Guidelines new version MPN
Association of non-malignant diseases with thrombocytosis: a prospective cohort study in general practice | British Journal of General Practice
Essential Thrombocythemia
Patients with triple-negative, JAK2V617F- and CALR-mutated essential thrombocythemia share a unique gene expression signature - ScienceDirect
Acute Leukaemias and Myeloid Neoplasms Part 4: Myeloproliferative Neoplasms
ESSENTIAL THROMBOCYTHEMIA (ET) – MPN Research Foundation
